BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Cash Flow Quality Index
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Cash Flow Quality Index of 1.43x as of June 2024. Operating cash flow of €8.36 Billion exceeds net income of €5.83 Billion, indicating high earnings quality where cash backs reported profits. Also explore R2WA total assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BEXIMCO PHARMA.GDR REGS 1 Cash Flow Quality Index (2022–2024)
Historical Cash Flow Quality Index for BEXIMCO PHARMA.GDR REGS 1 across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check R2WA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for BEXIMCO PHARMA.GDR REGS 1 (2022–2024)
Year-by-year earnings quality comparison for BEXIMCO PHARMA.GDR REGS 1. For live market cap and the full company financial profile, see BEXIMCO PHARMA.GDR REGS 1 market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.43x | €8.36 Billion | €5.83 Billion | ▲ +8.7% |
| 2023 | 1.32x | €6.08 Billion | €4.61 Billion | ▲ +29.6% |
| 2022 | 1.02x | €5.21 Billion | €5.12 Billion | — |